| Literature DB >> 27043356 |
Elham Abdollahi1,2,3, Fataneh Tavasolian4, Amir Abbas Momtazi-Borojeni3,5, Morteza Samadi6,7, Houshang Rafatpanah8,9.
Abstract
Interleukin-23 (IL-23) is a regulator of cellular immune responses involved in controlling infection and autoimmune diseases. Strong evidence has shown that IL-23 plays a role in the maintenance of immune responses by influencing the proliferation and survival of IL-17-producing T-helper (TH)-17 cells. The critical role of the IL-23/TH17 axis in immune-mediated diseases has emerged from different studies. It has also been seen that polymorphisms in the IL-23 receptor (IL-23R) gene might influence IL-23 responses. Interestingly, a functional single nucleotide polymorphism (SNP) in the IL-23 receptor gene (IL-23R; rs11209026, 1142 G wild-type A reduced function, Arg381Gln, R381Q) seems to confer a measure of protection against development of inflammatory bowel disease (IBD; Crohn's disease, ulcerative colitis), ankylosing spondylitis, rheumatoid arthritis, psoriasis, thyroiditis, recurrent spontaneous abortion and asthma, suggesting that a perturbation in the IL-23 signaling pathway is likely to be relevant to the pathophysiology of these diseases. The aim of this review was to provide an evaluation of what is currently known about the protective role of R381Q variant in IL-23R gene in immune-based diseases.Entities:
Keywords: IL-23R gene; R381Q (rs11209026) polymorphism; immune-mediated diseases
Mesh:
Substances:
Year: 2016 PMID: 27043356 DOI: 10.3109/1547691X.2015.1115448
Source DB: PubMed Journal: J Immunotoxicol ISSN: 1547-691X Impact factor: 3.000